BRPI0511089A - tieno[3,2-b]piridina-6-carbonitrilas como inibidores de cinase de proteìna - Google Patents

tieno[3,2-b]piridina-6-carbonitrilas como inibidores de cinase de proteìna

Info

Publication number
BRPI0511089A
BRPI0511089A BRPI0511089-0A BRPI0511089A BRPI0511089A BR PI0511089 A BRPI0511089 A BR PI0511089A BR PI0511089 A BRPI0511089 A BR PI0511089A BR PI0511089 A BRPI0511089 A BR PI0511089A
Authority
BR
Brazil
Prior art keywords
pyridine
protein kinase
kinase inhibitors
carbonitriles
thieno
Prior art date
Application number
BRPI0511089-0A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Nan Zhang
Ana Carolina Barrios Sosa
Haris Durutlic
Biqi Wu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149207&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0511089A publication Critical patent/BRPI0511089A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

TIENO¢3,2-b!PIRIDINA-6-CARBONITRILAS COMO INIBIDORES DE CINASE DE PROTEìNA. A presente invenção refere-se a prover compostos da fórmula II: em que: R¬ 1¬, R¬ 2¬ e X são R¬ 1¬ como definido mais abaixo no relatório, úteis no tratamento de câncer, acidente vascular cerebral, infarto do miocardio, dor neuropática, osteoporose, doença de rim policístico, doença auto-imune, artritre reumatóide, e rejeição de transplante. A invenção também provê processos para a produção dos ditos compostos.
BRPI0511089-0A 2004-05-14 2005-05-10 tieno[3,2-b]piridina-6-carbonitrilas como inibidores de cinase de proteìna BRPI0511089A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/845,710 US7276519B2 (en) 2002-11-25 2004-05-14 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
PCT/US2005/016150 WO2005113560A2 (en) 2004-05-14 2005-05-10 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
BRPI0511089A true BRPI0511089A (pt) 2007-12-26

Family

ID=35149207

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511089-0A BRPI0511089A (pt) 2004-05-14 2005-05-10 tieno[3,2-b]piridina-6-carbonitrilas como inibidores de cinase de proteìna

Country Status (20)

Country Link
US (2) US7276519B2 (pt)
EP (1) EP1756117A2 (pt)
JP (1) JP2007537262A (pt)
KR (1) KR20070015575A (pt)
CN (1) CN1950379A (pt)
AR (1) AR050248A1 (pt)
AU (1) AU2005245820A1 (pt)
BR (1) BRPI0511089A (pt)
CA (1) CA2564530A1 (pt)
CR (1) CR8787A (pt)
EC (1) ECSP067087A (pt)
GT (1) GT200500109A (pt)
MX (1) MXPA06012900A (pt)
NO (1) NO20065489L (pt)
PA (1) PA8633201A1 (pt)
PE (1) PE20060355A1 (pt)
RU (1) RU2006137476A (pt)
TW (1) TW200602348A (pt)
WO (1) WO2005113560A2 (pt)
ZA (1) ZA200609422B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101087787A (zh) 2004-12-23 2007-12-12 霍夫曼-拉罗奇有限公司 苯甲酰胺衍生物，它们的制备及作为药剂的应用
CN101830899A (zh) * 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
EP1965796A2 (en) * 2005-12-20 2008-09-10 Gilead Colorado, Inc. 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
WO2007146824A2 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
TW200900408A (en) * 2007-03-02 2009-01-01 Kyowa Hakko Kogyo Kk Fused pyridine derivative
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
CN102232071B (zh) * 2008-09-26 2016-03-23 财团法人卫生研究院 作为蛋白激酶抑制剂的稠合多环化合物
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
PT2812337T (pt) * 2012-02-09 2016-12-14 Merck Patent Gmbh Derivados de furo[3,2-b]piridina como inibidores de tbk1 e ikk
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
CZ20001709A3 (cs) 1997-11-11 2001-12-12 Pfizer Products Inc. Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi
BR9914164A (pt) * 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
PT1171440E (pt) 1999-04-21 2004-07-30 Wyeth Corp 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
JP2003519127A (ja) 1999-12-29 2003-06-17 ワイス 三環系タンパクキナーゼ阻害薬
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
ES2223827T3 (es) 2000-06-06 2005-03-01 Pfizer Products Inc. Derivados de tiofeno utiles como agentes anticancerigenos.
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
WO2002036570A1 (en) * 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
CN1523991A (zh) 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101796055B (zh) * 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa

Also Published As

Publication number Publication date
MXPA06012900A (es) 2007-01-26
TW200602348A (en) 2006-01-16
KR20070015575A (ko) 2007-02-05
RU2006137476A (ru) 2008-06-20
PA8633201A1 (es) 2006-05-16
US20080070913A1 (en) 2008-03-20
AR050248A1 (es) 2006-10-11
EP1756117A2 (en) 2007-02-28
AU2005245820A1 (en) 2005-12-01
CR8787A (es) 2007-10-02
US7276519B2 (en) 2007-10-02
CA2564530A1 (en) 2005-12-01
GT200500109A (es) 2005-12-23
US20040242883A1 (en) 2004-12-02
WO2005113560A2 (en) 2005-12-01
JP2007537262A (ja) 2007-12-20
NO20065489L (no) 2006-11-28
WO2005113560A3 (en) 2006-01-12
PE20060355A1 (es) 2006-05-11
ZA200609422B (en) 2008-07-30
CN1950379A (zh) 2007-04-18
ECSP067087A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
BRPI0511089A (pt) tieno[3,2-b]piridina-6-carbonitrilas como inibidores de cinase de proteìna
BR0316534A (pt) Tieno[3,2-b] piridina-6-carbonitrilas e tieno[2,3-b] piridina-5-carbonitrilas como inibidores das cinases protéicas
WO2009143018A3 (en) Pyrrolo [2, 3-d] pyrimidines as fm and kit kinase modulators
WO2008124083A3 (en) Aurora kinase modulators and method of use
DE502005009384D1 (de) Verfahren zur herstellung von sterilen suspensionen oder lyophilisaten schwerlöslicher basischer peptidkomplexe, diese enthaltende pharmazeutische for
ATE446946T1 (de) Neues verfahren zur salzherstellung
WO2005097832A3 (en) Humanized anti-tgf-beta antibodies
DE602005019465D1 (de) Bi- und trizyklische substituierte phenyl-methanone als inhibitoren von glycin-i (glyt-1)-transportern zur behandlung der alzheimer-krankheit
WO2007039319A8 (en) Dna microarray for rapid identification of candida albicans in blood cultures
TN2011000244A1 (en) Organic compounds
WO2007056170A3 (en) Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
IN2014KN00943A (pt)
SG170783A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
WO2006093923A8 (en) Treatment of bone disorders
WO2007025090A3 (en) Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
UA111594C2 (uk) Гетероциклічна сполука і її застосування
SG156650A1 (en) Thienopyrimidines useful as aurora kinase inhibitors
WO2007059905A3 (en) Thienopyrimidines treating inflammatory diseases
ATE478861T1 (de) Multizyklische verbindung und verwendungsverfahren
WO2014047463A3 (en) Libraries of compounds having desired properties and methods for making and using them
WO2010125216A3 (es) Preparación de compuestos 5,6-dihidropirido[2,3-d]pirimidin-7(8h)-ona sustituidos
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
EP1802969A4 (en) PROCESS FOR THE PRODUCTION OF MOLECULAR FOOTPRINTED POLYMERS FOR THE RECOGNITION OF TARGET MOLECULES
EP2546256A3 (en) Process for the synthesis of intermediates compounds useful for the preparation of E1 activity activating enzyme inhibitors
WO2006122769A3 (de) Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.